Cargando…
An All-Harm Index Quantifying Central Line Associated Infectious and Noninfectious Complications Among Pediatric Oncology Patients
BACKGROUND: In contrast to inpatient central line associated blood stream infections (CLABSIs), little attention has been devoted to preventing outpatient CLABSIs or central line associated noninfectious complications (CLANCs). Our aim was to develop and validate a novel index to comprehensively qua...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5631131/ http://dx.doi.org/10.1093/ofid/ofx163.1839 |
_version_ | 1783269376305135616 |
---|---|
author | Kelada, Aml Foster, Timothy Worley, Sarah Tang, Anne Arakoni, Venkatraman B Foster, Charles |
author_facet | Kelada, Aml Foster, Timothy Worley, Sarah Tang, Anne Arakoni, Venkatraman B Foster, Charles |
author_sort | Kelada, Aml |
collection | PubMed |
description | BACKGROUND: In contrast to inpatient central line associated blood stream infections (CLABSIs), little attention has been devoted to preventing outpatient CLABSIs or central line associated noninfectious complications (CLANCs). Our aim was to develop and validate a novel index to comprehensively quantify the rates of both CLABSIs and CLANCs among pediatric oncology patients. METHODS: CLABSIs were defined according to CDC/NHSN definitions. CLANCs were defined using a novel classification as noninfectious events resulting in premature removal of the line. 592 oncology patient records (< 24 years; 2006–16) were reviewed. Wilcoxon rank-sum tests were used for continuous and ordinal characteristics and Chi-square or Fisher’s exact tests for categorical characteristics. RESULTS: 656 CVCs were inserted in 368 patients, for a total of 175,941catheter days (9.6% inpatient). Events included: 108 CLABSIs (42 inpatient and 66 outpatient) and 89 CLANCs (44 inpatient and 45 outpatient). The all-harm event rate was 1.1 per 1000 CVC days; the sum of CLABSI (0.61) and CLANC (0.50) rates. Inpatient rates were: all-harm (4.9), CLABSIs (2.4), and CLANCs (2.5). Outpatient event rates were: all-harm (0.72), CLABSIs (0.45), and CLANCs (0.27). For all lines treated independently, risk ratio of an adverse event was strongly correlated with CVC type (tunneled CVCs vs ports; 11.8; <0.001), age at placement per 1 year older (0.89; <0.001), gender (females vs males; 1.6; 0.021), and tumor type (AML vs Non-AML Leukemia/Lymphoma; 4.0; <0.001). Tunneled CVCs carried greater risk for both CLABSI (10.8; <0.001) and CLANC (13.2; <0.001) than ports. CONCLUSION: We have developed an all-harm index to quantify the total harm associated with central line use. Among pediatric oncology patients with CVCs, major noninfectious complications occur at rates similar to those reported for CLABSIs. Although event rates per 1000 CVC days were lower among outpatients, the total number of infectious and noninfectious harm events was similar in the inpatient and outpatient settings. Additional quality improvement efforts are required to reduce the total harm associated with CVC use, and modifiable factors such as catheter choice could significantly impact the rate of both CLABSIs and CLANCs. DISCLOSURES: All authors: No reported disclosures. |
format | Online Article Text |
id | pubmed-5631131 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-56311312017-11-07 An All-Harm Index Quantifying Central Line Associated Infectious and Noninfectious Complications Among Pediatric Oncology Patients Kelada, Aml Foster, Timothy Worley, Sarah Tang, Anne Arakoni, Venkatraman B Foster, Charles Open Forum Infect Dis Abstracts BACKGROUND: In contrast to inpatient central line associated blood stream infections (CLABSIs), little attention has been devoted to preventing outpatient CLABSIs or central line associated noninfectious complications (CLANCs). Our aim was to develop and validate a novel index to comprehensively quantify the rates of both CLABSIs and CLANCs among pediatric oncology patients. METHODS: CLABSIs were defined according to CDC/NHSN definitions. CLANCs were defined using a novel classification as noninfectious events resulting in premature removal of the line. 592 oncology patient records (< 24 years; 2006–16) were reviewed. Wilcoxon rank-sum tests were used for continuous and ordinal characteristics and Chi-square or Fisher’s exact tests for categorical characteristics. RESULTS: 656 CVCs were inserted in 368 patients, for a total of 175,941catheter days (9.6% inpatient). Events included: 108 CLABSIs (42 inpatient and 66 outpatient) and 89 CLANCs (44 inpatient and 45 outpatient). The all-harm event rate was 1.1 per 1000 CVC days; the sum of CLABSI (0.61) and CLANC (0.50) rates. Inpatient rates were: all-harm (4.9), CLABSIs (2.4), and CLANCs (2.5). Outpatient event rates were: all-harm (0.72), CLABSIs (0.45), and CLANCs (0.27). For all lines treated independently, risk ratio of an adverse event was strongly correlated with CVC type (tunneled CVCs vs ports; 11.8; <0.001), age at placement per 1 year older (0.89; <0.001), gender (females vs males; 1.6; 0.021), and tumor type (AML vs Non-AML Leukemia/Lymphoma; 4.0; <0.001). Tunneled CVCs carried greater risk for both CLABSI (10.8; <0.001) and CLANC (13.2; <0.001) than ports. CONCLUSION: We have developed an all-harm index to quantify the total harm associated with central line use. Among pediatric oncology patients with CVCs, major noninfectious complications occur at rates similar to those reported for CLABSIs. Although event rates per 1000 CVC days were lower among outpatients, the total number of infectious and noninfectious harm events was similar in the inpatient and outpatient settings. Additional quality improvement efforts are required to reduce the total harm associated with CVC use, and modifiable factors such as catheter choice could significantly impact the rate of both CLABSIs and CLANCs. DISCLOSURES: All authors: No reported disclosures. Oxford University Press 2017-10-04 /pmc/articles/PMC5631131/ http://dx.doi.org/10.1093/ofid/ofx163.1839 Text en © The Author 2017. Published by Oxford University Press on behalf of Infectious Diseases Society of America. http://creativecommons.org/licenses/by-nc-nd/4.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com |
spellingShingle | Abstracts Kelada, Aml Foster, Timothy Worley, Sarah Tang, Anne Arakoni, Venkatraman B Foster, Charles An All-Harm Index Quantifying Central Line Associated Infectious and Noninfectious Complications Among Pediatric Oncology Patients |
title | An All-Harm Index Quantifying Central Line Associated Infectious and Noninfectious Complications Among Pediatric Oncology Patients |
title_full | An All-Harm Index Quantifying Central Line Associated Infectious and Noninfectious Complications Among Pediatric Oncology Patients |
title_fullStr | An All-Harm Index Quantifying Central Line Associated Infectious and Noninfectious Complications Among Pediatric Oncology Patients |
title_full_unstemmed | An All-Harm Index Quantifying Central Line Associated Infectious and Noninfectious Complications Among Pediatric Oncology Patients |
title_short | An All-Harm Index Quantifying Central Line Associated Infectious and Noninfectious Complications Among Pediatric Oncology Patients |
title_sort | all-harm index quantifying central line associated infectious and noninfectious complications among pediatric oncology patients |
topic | Abstracts |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5631131/ http://dx.doi.org/10.1093/ofid/ofx163.1839 |
work_keys_str_mv | AT keladaaml anallharmindexquantifyingcentrallineassociatedinfectiousandnoninfectiouscomplicationsamongpediatriconcologypatients AT fostertimothy anallharmindexquantifyingcentrallineassociatedinfectiousandnoninfectiouscomplicationsamongpediatriconcologypatients AT worleysarah anallharmindexquantifyingcentrallineassociatedinfectiousandnoninfectiouscomplicationsamongpediatriconcologypatients AT tanganne anallharmindexquantifyingcentrallineassociatedinfectiousandnoninfectiouscomplicationsamongpediatriconcologypatients AT arakonivenkatraman anallharmindexquantifyingcentrallineassociatedinfectiousandnoninfectiouscomplicationsamongpediatriconcologypatients AT bfostercharles anallharmindexquantifyingcentrallineassociatedinfectiousandnoninfectiouscomplicationsamongpediatriconcologypatients AT keladaaml allharmindexquantifyingcentrallineassociatedinfectiousandnoninfectiouscomplicationsamongpediatriconcologypatients AT fostertimothy allharmindexquantifyingcentrallineassociatedinfectiousandnoninfectiouscomplicationsamongpediatriconcologypatients AT worleysarah allharmindexquantifyingcentrallineassociatedinfectiousandnoninfectiouscomplicationsamongpediatriconcologypatients AT tanganne allharmindexquantifyingcentrallineassociatedinfectiousandnoninfectiouscomplicationsamongpediatriconcologypatients AT arakonivenkatraman allharmindexquantifyingcentrallineassociatedinfectiousandnoninfectiouscomplicationsamongpediatriconcologypatients AT bfostercharles allharmindexquantifyingcentrallineassociatedinfectiousandnoninfectiouscomplicationsamongpediatriconcologypatients |